Ergomed Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 2yrs |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
Is It Time To Consider Buying Ergomed plc (LON:ERGO)?
Aug 19
At UK£9.74, Is Ergomed plc (LON:ERGO) Worth Looking At Closely?
Apr 12Ergomed plc (LON:ERGO) Shares Could Be 21% Below Their Intrinsic Value Estimate
Oct 29Should You Be Adding Ergomed (LON:ERGO) To Your Watchlist Today?
Jul 14Why Ergomed plc (LON:ERGO) Could Be Worth Watching
Jun 12Calculating The Fair Value Of Ergomed plc (LON:ERGO)
Apr 07Does Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?
Mar 19Why Ergomed plc (LON:ERGO) Could Be Worth Watching
Mar 01Calculating The Fair Value Of Ergomed plc (LON:ERGO)
Dec 15I Ran A Stock Scan For Earnings Growth And Ergomed (LON:ERGO) Passed With Ease
Nov 24Calculating The Intrinsic Value Of Ergomed plc (LON:ERGO)
Aug 28If You Like EPS Growth Then Check Out Ergomed (LON:ERGO) Before It's Too Late
Jul 31Getting In Cheap On Ergomed plc (LON:ERGO) Might Be Difficult
Jul 06Ergomed plc (LON:ERGO) Shares Could Be 31% Above Their Intrinsic Value Estimate
May 21Do Ergomed's (LON:ERGO) Earnings Warrant Your Attention?
Mar 26If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today
Feb 22Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Jan 18Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price
Dec 13We Think Ergomed's (LON:ERGO) Statutory Profit Might Understate Its Earnings Potential
Nov 23CEO
Ergomed has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 6.3yrs | UK£964.30k | 17.53% £ 122.9m | |
| Chief Transformation & Technology Officer | less than a year | UK£52.77k | no data | |
| CFO & Executive Director | less than a year | no data | no data | |
| Head of Risk Management & Pharmacoepidemiology | 5.5yrs | no data | no data | |
| President of PrimeVigilance | no data | no data | no data | |
| President of Clinical Research | no data | no data | no data | |
| Senior Vice President of Global Development | 2yrs | no data | no data | |
| Senior Vice-President of Capital Markets & Strategy | 1.8yrs | no data | no data | |
| Company Secretary | 4.2yrs | no data | no data |
2.0yrs
Average Tenure
62yo
Average Age
Experienced Management: ERGO's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 6.3yrs | UK£964.30k | 17.53% £ 122.9m | |
| CFO & Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 2.4yrs | UK£52.72k | no data | |
| Independent Non-Executive Director | 2.6yrs | UK£52.72k | no data | |
| Independent Non-Executive Director | 1.4yrs | UK£27.89k | no data | |
| Senior Independent Director | 1.7yrs | UK£49.15k | no data |
2.0yrs
Average Tenure
61yo
Average Age
Experienced Board: ERGO's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/13 02:10 |
| End of Day Share Price | 2023/11/13 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ergomed plc is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samuel England | Berenberg |
| Colin Grant | Davy |
| Jonas Peciulis | Edison Investment Research |